IMTX (Immatics N.V.) Market Value to Book Value Ratio

Immatics N.V. (IMTX) is minimizing the risks of narrow specialization in T-cell methods by securing external funding and global alliances. The business valuation, which currently stands at 2.18, depends on medical research outcomes rather than macroeconomic fluctuations. This share price chart on GURU.Markets reflects the dynamics of a company accelerating vaccine production through technological symbiosis with pharmaceutical behemoths.

Immatics Biotechnologies (IMTX): Capitalization to Book Value Ratio from 07/04/2022 to 10/28/2026

Financial and market metric breakdowns for Immatics NV (IMTX)

- price and consensus price forecast:

Stock Quotes Immatics N.V.|IMTX - Broker Consensus Forecast

- market capitalization data:

Market Value Immatics Corp|IMTX - Total Enterprise Value

- book capitalization data:

Net Assets per Single Share Immatics|IMTX - Accounting Capitalization|Market Capitalization to Book Value Ratio immatics.com|IMTX - Cumulative Company Assets

- debt and liquidity data:

Debt to Equity Immatics N.V.|IMTX - Long-Term Liabilities to Capital|Short-Term Debt to Equity Immatics Corp|IMTX - Company Debts|Debt to Book Capitalization Ratio Immatics Corp

Fundamental valuation:Immatics N.V.

To protect capital during portfolio construction, it is critical to assess the margin of safety by comparing the business's market value to its net assets. This price-to-book ratio measures the market premium over the balance sheet of Immatics N.V. (IMTX), reflecting investor expectations for the success of T-cell therapy and strategic alliances amid high clinical development costs.

Competitor analysis